Incyte’s Vega Therapeutics acquisition comes with a late-stage drug offering a novel mechanism of action and a dosing advantage compared to currently available therapies for von Willebrand disease, an inherited bleeding disorder. The deal comes as patent expiration looms for Jakafi, currently Incyte’s top product.
The post Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug appeared first on MedCity News.
